All

What are you looking for?

All
Projects
Results
Organizations

Quick search

  • Projects supported by TA ČR
  • Excellent projects
  • Projects with the highest public support
  • Current projects

Smart search

  • That is how I find a specific +word
  • That is how I leave the -word out of the results
  • “That is how I can find the whole phrase”

Patient-Derived Xenograft Models: An Emerging Platform for Translational Cancer Research

The result's identifiers

  • Result code in IS VaVaI

    <a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216224%3A14110%2F14%3A00078130" target="_blank" >RIV/00216224:14110/14:00078130 - isvavai.cz</a>

  • Result on the web

    <a href="http://dx.doi.org/10.1158/2159-8290.CD-14-0001" target="_blank" >http://dx.doi.org/10.1158/2159-8290.CD-14-0001</a>

  • DOI - Digital Object Identifier

    <a href="http://dx.doi.org/10.1158/2159-8290.CD-14-0001" target="_blank" >10.1158/2159-8290.CD-14-0001</a>

Alternative languages

  • Result language

    angličtina

  • Original language name

    Patient-Derived Xenograft Models: An Emerging Platform for Translational Cancer Research

  • Original language description

    Recently, there has been an increasing interest in the development and characterization of patient-derived tumor xenograft (PDX) models for cancer research. PDX models mostly retain the principal histologic and genetic characteristics of their donor tumor and remain stable across passages. These models have been shown to be predictive of clinical outcomes and are being used for preclinical drug evaluation, biomarker identification, biologic studies, and personalized medicine strategies. This article summarizes the current state of the art in this field, including methodologic issues, available collections, practical applications, challenges and shortcomings, and future directions, and introduces a European consortium of PDX models. Significance: PDX models are increasingly used in translational cancer research. These models are useful for drug screening, biomarker development, and the preclinical evaluation of personalized medicine strategies.

  • Czech name

  • Czech description

Classification

  • Type

    J<sub>x</sub> - Unclassified - Peer-reviewed scientific article (Jimp, Jsc and Jost)

  • CEP classification

    FD - Oncology and haematology

  • OECD FORD branch

Result continuities

  • Project

  • Continuities

    I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Others

  • Publication year

    2014

  • Confidentiality

    S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Data specific for result type

  • Name of the periodical

    Cancer Discovery

  • ISSN

    2159-8274

  • e-ISSN

  • Volume of the periodical

    4

  • Issue of the periodical within the volume

    9

  • Country of publishing house

    US - UNITED STATES

  • Number of pages

    16

  • Pages from-to

    998-1013

  • UT code for WoS article

    000343121400023

  • EID of the result in the Scopus database